Global Genomic Cancer Panel and Profiling Markets (2020 to 2024) - Featuring Agena Bioscience, Agilent & Almac Diagnostics Among Others -

DUBLIN--()--The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to's offering.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using the information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. And there is a lot of information to be had. But the COVID-19 Pandemic has impacted the market. Find out how in this thorough report.

Comprehensive panels, genomic profiling, high-risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are already taking the lead. It is a dynamic market situation with an enormous opportunity where the right diagnostic with the right support can command premium pricing. And science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

Cancer Panel Market - Strategic Situation Analysis & COVID Update

  • Guide for Executives, Marketing, Sales and Business Development Staff
  • Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

2. Market Overview

2.1 Players in a Dynamic Market

2.2 Oncogenomics

2.3 Cancer Management vs. Diagnosis

2.4 Phases of Adoption - Looking into The Future

2.5 Structure of Industry Plays a Part

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Level of Care

3.1.2 Companion Dx

3.1.3 Immuno-oncology

3.1.4 Liability

3.1.5 Aging Population

3.2 Factors Limiting Growth

3.2.1 State of knowledge

3.2.2 Genetic Blizzard.

3.2.3 Protocol Resistance

3.2.4 Regulation and coverage

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution

3.4.2 Single Cell Genomics Changes the Picture

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 CGES Testing, A Brave New World

3.4.5 Biochips/Giant magnetoresistance based assay

4. Cancer Panels & Profiles Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Cancer Gene Panels and Profiles

6.1 Global Market Overview by Country

6.2 Global Market by Cancer Type - Overview

6.3 Global Market Germline & Somatic - Overview

7. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer

7.1 Comprehensive Panels & Profiles

7.2 Breast Cancer Gene Testing

7.3 Colorectal Cancer Gene Testing

7.4 Gynecological Cancer Gene Testing

7.5 Blood Cancer Gene Testing

7.6 Prostate Cancer Gene Testing

7.7 Lung Cancer Gene Testing

7.8 Other Cancer Gene Testing

8. Global Cancer Gene Testing Markets - Germline and Somatic

8.1 Global Market Somatic

8.3 Global Market Germline

9. Potential Market Opportunity Sizes

9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal

9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer

9.3 Potential Market Size - Cancer Diagnosis

9.4 Potential Market Size - Therapy Selection

Companies Mentioned

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Almac Diagnostics
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc
  • BioFluidica
  • bioMrieux Diagnostics
  • Bioneer Corporation
  • Bioview
  • Blueprint Genetics
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • And Many More Companies!

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900